v3.25.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Stock-Based Compensation

NOTE 9 STOCK-BASED COMPENSATION

2021 Equity Incentive Plan

Effective June 9, 2021, the Company’s Board of Directors (the "Board") and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Equity Incentive Plan (the “2021 Equity Incentive Plan”). The 2021 Equity Incentive Plan permits the grant of awards or restricted or unrestricted common stock, stock options, stock appreciation rights, restricted stock units, performance awards, and other stock-based awards to employees and directors of, and consultants and advisors to, the Company and its affiliates. On January 1, 2025, the number of shares of common stock reserved and available for issuance under the 2021 Equity Incentive Plan increased by 19,137 shares.

Restricted Stock Awards ("RSA")

The following is a summary of RSA transactions as of and for the three months ended March 31, 2025:

 

 

Unvested Shares

 

 

Weighted-Average
Grant Date Fair Value

 

Unvested, December 31, 2024

 

 

2,255

 

 

$

11.98

 

Vested

 

 

—

 

 

 

11.98

 

Forfeited

 

 

(13

)

 

 

11.98

 

Unvested, March 31, 2025

 

 

2,242

 

 

$

11.98

 

Restricted Stock Units ("RSU")

The following is a summary of RSU transactions as of and for the three months ended March 31, 2025:

 

 

Unvested Shares

 

 

Weighted-Average
Grant Date Fair Value

 

Outstanding, December 31, 2024

 

 

24,003

 

 

$

6.72

 

Granted

 

 

11,965

 

 

 

7.80

 

Vested

 

 

(6,104

)

 

 

7.03

 

Canceled and forfeited

 

 

(2,047

)

 

 

7.17

 

Outstanding, March 31, 2025

 

 

27,817

 

 

$

7.09

 

Stock Options

The following is a summary of stock option activity as of and for the three months ended March 31, 2025:

 

 

Number of Options

 

 

Weighted-Average
Exercise Price

 

 

Weighted-Average
Remaining Contractual Term (Years)

 

 

Aggregate Intrinsic Value

 

Outstanding, December 31, 2024

 

 

13,476

 

 

$

7.42

 

 

 

6.43

 

 

$

2,300

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

—

 

Canceled and forfeited

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Outstanding, March 31, 2025

 

 

13,476

 

 

$

7.42

 

 

 

6.18

 

 

$

1,413

 

Exercisable at March 31, 2025

 

 

2,246

 

 

$

7.42

 

 

 

6.22

 

 

$

235

 

Vested or expected to vest at March 31, 2025

 

 

13,476

 

 

$

7.42

 

 

 

6.18

 

 

$

1,413

 

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense related to RSUs and stock options within general and administrative expenses in the unaudited consolidated statements of operations and comprehensive income (loss) as follows:

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Stock-based compensation expense

 

$

18,584

 

 

$

20,581

 

As of March 31, 2025, the Company had $183,919 in unrecognized compensation expense related to all non-vested RSUs and stock options that will be recognized over the weighted-average remaining service period of 2.7 years.

2021 Employee Stock Purchase Plan

Effective June 9, 2021, the Board and its stockholders as of that date adopted and approved the LifeStance Health Group, Inc. 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP is more fully described in Note 11 in the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

As of March 31, 2025, no shares of common stock have been purchased under the Company’s ESPP.